Occupy Corporatism
by Susanne Posel
The Obama administration is requesting Congress give them $30 million to hand over to the Centers for Disease Control and Prevention (CDC) for efforts to contain Ebola outbreaks in Africa and $58 million to produce the experimental drugs that have been used to treat the Americans who have contracted the virus.
Part of the intention of the $30 million is to pay for agency epidemiologists and intelligence officers who are tracing the spread of the disease in Africa”, increasing the number of staff from 100 to 150 or more; as well as affording more staff in the U.S.
The CDC would be allowed to take the experimental drug ZMapp to western Africa and purchase more from the manufacturer to keep afloat the two vaccines being funded.
In addition, $10 million of unused cash would be funneled to the Department of Health and Human Services (DHHS) “to help with the Ebola outbreak in Africa”.
President Obama spoke to the people of Africa in Sierra Leone, Liberia and Nigeria in a YouTube video, addressing “misconceptions” about the Ebola virus.
An unnamed spokesperson allegedly working with the Department of State explained that the American embassies would be used to “disseminate” this video “in the region” and have the contents “translated into local languages”.
The anonymous official is quoted as saying: “The target audience is West Africans, and we’re doing all we can to make sure it reaches the hardest-hit areas.”
Obama said in the video: The United States is working with your governments to help stop this disease, and the first step in this fight is knowing the facts.”
Mapp Biopharmaceutical (MBP) is the de jour drug company for Ebola treatments; as well as Emory University Hospital (EUH), one of the locations housing of the infected Americans.
In fact, EUH and Samaritan’s Purse collaborated with MBP to ensure the experimental treatment was available to the Ebola patient.
MBP has been researching with the US Army for more than 10 years to produce treatments and vaccines for Ebola; as well as other “potential bio-warfare agents”.
Charles Arntzen, plant biotechnology expert with MBP commented: “The tobacco plant production system was developed because it was a method that could produce antibodies rapidly in the event of an emergency. To produce therapeutic proteins inside a tobacco plant, genes for the desired antibodies are fused to genes for a natural tobacco virus. The tobacco plants are then infected with this new artificial virus.”
Arntzen explained: “The infection results in the production of antibodies inside the plant. The plant is eventually ground up and the antibody is extracted. The whole process takes a matter of weeks.”
An “antibody cocktail” that is believed to boost the human immune system is being “developed” by MBP with Defyrus, Inc.
Larry Zeitlin, president of MBP commented: “With the sporadic nature of Ebola outbreaks, combined with the absolute deadly nature of the virus makes it a hard sell to large pharmaceutical corporations because it isn’t a huge customer base and big pharma is obviously interested in big profits. So these niche products which are important for biodefense are really driven by small companies.”
ConspiracyAnalyst.org 